Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953275 · ClinicalTrials.gov registry record · Early Phase 1
Synergistic Effect of Vedolizumab and Pentoxifylline
A Early Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 37
- Enrollment target
NCT02953275 is a Early Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 37 participants.
The verdict
NCT02953275, a Early Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the synergistic effect and clinical benefits of vedolizumab and pentoxifylline in the management of patients with inflammatory bowel disease.
Interventions
- DRUG placebo
- DRUG Pentoxifylline
- DRUG vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-04-13 |
| Est. Completion | 2019-06-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953275
The ClinicalTrials.gov registry entry for NCT02953275 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02953275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953275 about?
NCT02953275 is a clinical study titled "Synergistic Effect of Vedolizumab and Pentoxifylline". The purpose of this study is to determine the synergistic effect and clinical benefits of vedolizumab and pentoxifylline in the management of patients with inflammatory bowel disease.
What is the current status of trial NCT02953275?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 37 participants. The study started on 2017-04-13. Estimated completion is 2019-06-13.
What interventions are being tested in trial NCT02953275?
The interventions under investigation include: placebo (DRUG), Pentoxifylline (DRUG), vedolizumab (DRUG).
Who is sponsoring clinical trial NCT02953275?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.